Derik de Bruin

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating on Catalent (NYSE: CTLT), and raised the price target from $26.00 to $28.00. In the report, Bank of America noted, “F1Q revenues of $418mn (+1% y/y, +1% constant currency (‘CC')) were above our $406mn (-1.9...

In a report published Monday, Bank of America analyst Derik de Bruin reiterated a Buy rating on Agilent Technologies (NYSE: A), but lowered the price target from $64.00 to $59.00. In the report, Bank of America noted, “On Monday (10/20), Agilent (A) and Keysight (KEYS) will begin trading separately...

In a report published Thursday, Bank of America analyst Derik de Bruin reiterated a Buy rating on FEI Company (NASDAQ: FEIC), but lowered the price target from $100.00 to $96.00. In the report, Bank of America noted, “FEIC reported total revenues of $237mn (+6.5% y/y, +5.3% organic, -0.2% F/X, +1.4...

In a report published Friday, Bank of America analyst Derik de Bruin reiterated an Underperform rating on Affymetrix (NASDAQ: AFFX), and raised the price target from $7.00 to $7.50. In the report, Bank of America noted, “Affymetrix is a pioneer in the development and commercialization of DNA...

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating on Thermo Fisher Scientific (NYSE: TMO), and raised the price target from $128.00 to $142.00. In the report, Derik de Bruin noted, “Following our visit to TMO's mass spectrometry facility (link), we are...

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating on Quintiles Transnational Holdings (NYSE: Q), and raised the price target from $55.00 to $60.00. In the report, Bank of America noted, “We are positive on Quintiles' outlook as industry challenges ease...

In a report published Wednesday, Bank of America analyst Derik de Bruin reiterated an Underperform rating on Genomic Health (NASDAQ: GHDX), but lowered the price target from $30.00 to $28.00. In the report, Bank of America noted, “GHDX expects to deliver 15-20% test vol. growth in FY14 , assuming...

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating and $25.00 price target on Bruker Corporation (NASDAQ: BRKR). In the report, Bank of America noted, “On 11/26, BRKR announced that it received 510-k approval for its MALDI Biotyper CA System, a mass...

In a report published Wednesday, Bank of America analyst Derik de Bruin downgraded the rating on Waters Corporation (NYSE: WAT) from Buy to Neutral, and lowered the price target from $113.00 to $105.00. In the report, Bank of America noted, “On 10/22 WAT reported 3Q13 earnings results that were...

In a report published Tuesday, Bank of America analyst Derik de Bruin downgraded the rating on Cepheid (NASDAQ: CPHD) from Buy to Neutral, but raised the price target from $39.00 to $41.00. In the report, Bank of America noted, “While we remain positive on CPHD's technology and progress in...

In a report published Tuesday, Bank of America analyst Derik de Bruin downgraded the rating on Genomic Health (NASDAQ: GHDX) from Neutral to Underperform, and lowered the price target from $36.00 to $33.00. In the report, Bank of America noted, “While we are impressed by GHDX's execution and are...

In a report published Friday, Bank of America analyst Derik de Bruin upgraded Bruker (NASDAQ: BRKR) from Neutral to Buy, and raised the price target from $20.00 to $26.00. In the report, Bank of America noted, “We have been positive on BRKR's technology, as most years BRKR has organically grown...

In a report published Tuesday, Bank of America analyst Derik de Bruin initiated coverage on Quintiles Transnational (NYSE: Q) with a Buy rating and $51.00 price target. In the report, Bank of America noted, “We are positive on Quintiles' outlook as industry challenges ease and as the company's...

In a report published Tuesday, Bank of America analyst Derik de Bruin downgraded the rating on Genomic Health (NASDAQ: GHDX) from Buy to Neutral, and lowered the price target from $43.00 to $36.00. In the report, Bank of America noted, “We are impressed by Genomic Health's scientific and...

In a report published on Friday, Bank of America analyst Derik de Bruin downgraded its rating on Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral. Bank of America also lowered its price target on the company from $37 to $35. In the report, Bank of America commented that, "Yesterday, the...